On November 8th, good news came from Wanbangde Pharmaceutical - after strict on-site inspection by Zhejiang Food and Drug Administration, the two small-volume injection (non-terminal sterilization) production lines in Area A of the second injection workshop of the company successfully passed the GMP certification and obtained the Obtained the national drug production GMP certificate. This marks that Wanbangde Pharmaceutical's sterile preparation production technology, quality control and quality assurance have jumped to a new level, and at the same time, it has laid a solid foundation for the company to enter the big health industry.

The GMP certification was launched from September 27th to September 30th. An inspection team composed of five members from Zhejiang Food and Drug Administration conducted on-site inspections on the production and quality management of small-volume injections in Area A of Wanbangde Pharmaceutical Injections Workshop II. During the four-day inspection process, the inspection team experts listened carefully to the report of the company's deputy general manager Lin Hong, and strictly followed GMP requirements, from quality management, quality assurance, materials and products, document management, self-inspection, product delivery and recall. , production management, plant and facility equipment, etc., conduct on-site inspections on dozens of software and hardware facilities such as the company's production workshops, water production and public systems, quality control laboratories, storage centers, etc. adequate communication and exchange. Finally, after a comprehensive discussion by the expert group, it was concluded that the two production lines of small-volume injections (non-terminal sterilization) were in compliance with the regulations of drug GMP, and it was determined that the enterprise passed the on-site inspection of GMP certification.

The two small-volume injection (non-terminal sterilization) production lines within the scope of this GMP certification mainly produce small-volume injections involving 40 product specifications, including Huperzine A injection and ribavirin injection. The passing of GMP certification has greatly improved the company's product quality and economic benefits, and its competitiveness has also been significantly enhanced.

In the next step, Wanbangde Pharmaceutical will take the certification work as a new starting point for quality management, continuously improve and improve the quality system, strengthen the control of key internal and external quality factors, and achieve scientific and comprehensive management and strict monitoring in the entire process of drug production to promote product quality. Reach the leading level at home and abroad, and achieve quality management in line with international standards. At the same time, we will accelerate the adjustment, transformation and upgrading of the enterprise structure, aiming at the international cutting-edge high-tech, and speeding up the entry of the company's drugs into the mainstream international markets in Europe and the United States.